Karen Dah, MD
Nephrology · Salisbury, MDNPI 1730467804
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 422 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Among nephrology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 422 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$1K
- Amgen$1K
- AstraZeneca$1K
- Akebia Therapeutics Inc$590
- OPKO Pharmaceuticals, LLC$554
- Bayer$512
- plus $4K from 22 others
What the payments were for
- Food & beverage$8,63295%
- Education$4475%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 46 | $1,393 |
| Amgen(2 entities) | 55 | $1,172 |
| AstraZeneca(2 entities) | 54 | $1,016 |
| Akebia Therapeutics Inc | 31 | $590 |
| OPKO Pharmaceuticals, LLC | 25 | $554 |
| Bayer | 25 | $512 |
| Fresenius USA Marketing, Inc. | 24 | $503 |
| Vifor Pharma, Inc. | 23 | $457 |
| Aurinia Pharma U.S., Inc. | 19 | $455 |
| Otsuka America Pharmaceutical, Inc. | 22 | $383 |
| Ardelyx, Inc. | 15 | $275 |
| Calliditas Therapeutics US Inc. | 13 | $263 |
| GSK | 12 | $257 |
| Novartis | 12 | $248 |
| Travere Therapeutics, Inc. | 13 | $210 |
| Mallinckrodt Enterprises LLC | 5 | $173 |
| Lilly USA, LLC | 6 | $135 |
| ANI Pharmaceuticals, Inc. | 5 | $114 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $79 |
| Sunovion Pharmaceuticals Inc. | 3 | $52 |
| Philips North America LLC | 1 | $47 |
| Kyowa Kirin, Inc. | 2 | $47 |
| Boehringer Ingelheim | 2 | $36 |
| Shire North American Group Inc | 2 | $30 |
| Scpharmaceuticals Inc. | 1 | $27 |
| Genentech USA, Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$125
How this compares
$9,080 in reported general payments places this provider in the 90th percentile of 285 nephrology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeltassaPatiromer Calcium Sorbitex | 22 | $49,438 |
| LokelmaSodium Zirconium Cyclosilicate | 18 | $28,021 |
| FarxigaDapagliflozin Propanediol | 15 | $23,887 |
| Sevelamer Carbonate | 37 | $9,261 |
| Calcium Acetate | 27 | $5,764 |
| Calcitriol | 47 | $1,201 |
| Hydralazine Hcl | 44 | $789 |
| Nifedipine ErNifedipine | 18 | $615 |
| Amlodipine Besylate | 55 | $459 |
| Metoprolol Succinate | 24 | $363 |
| Potassium Chloride | 17 | $353 |
| Atorvastatin Calcium | 17 | $273 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 22 | $198 |
| Losartan Potassium | 18 | $178 |
| Carvedilol | 24 | $164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLokelma, Farxiga | $1,016 | $51,90833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 285 nephrology providers in Maryland.
Other nephrology in Salisbury
- Kazi KhanSalisbury$8K
- Kiran SamindlaFrederick$491K
- Matthew WeirBaltimore$490K
- Chirag ParikhBaltimore$186K
- Mohamad HanounehBaltimore$174K
- Daniel BrennanBaltimore$133K
- Monika DhillonBaltimore$126K
- Duvuru GeethaBaltimore$91K
- Eli RozaHagerstown$79K
- Mohamed AttaBaltimore$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.